{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T01:21:07Z","timestamp":1787707267462,"version":"build-2784847793"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75386-x","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:44:43Z","timestamp":1784904283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+\/HER2- breast cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Jia-Yang","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5728-0272","authenticated-orcid":false,"given":"Fang-Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Andriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Yong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5113-2332","authenticated-orcid":false,"given":"Da-Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-148X","authenticated-orcid":false,"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"75386_CR1","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1172\/JCI33295","volume":"117","author":"K Polyak","year":"2007","unstructured":"Polyak, K. Breast cancer: origins and evolution. J. Clin. Investig. 117, 3155\u20133163 (2007).","journal-title":"J. Clin. Investig."},{"key":"75386_CR2","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1200\/JCO.2008.18.1024","volume":"27","author":"J Hugh","year":"2009","unstructured":"Hugh, J. et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27, 1168\u20131176 (2009).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"75386_CR3","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch, A. et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 22, 1736\u20131747 (2011).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"75386_CR4","first-page":"480","volume":"73","author":"LA Huppert","year":"2023","unstructured":"Huppert, L. A., Gumusay, O., Idossa, D. & Rugo, H. S. Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J. Clin. 73, 480\u2013515 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"75386_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M. & Schiff, R. ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat. Rev. Clin. Oncol. 12, 573\u2013583 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75386_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06309-8","volume":"9","author":"A Gao","year":"2018","unstructured":"Gao, A. et al. LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4\/6-Rb and ER\u03b1 pathway. Nat. Commun. 9, 4180 (2018).","journal-title":"Nat. Commun."},{"key":"75386_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","volume":"1","author":"TW Miller","year":"2011","unstructured":"Miller, T. W. et al. ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 1, 338\u2013351 (2011).","journal-title":"Cancer Discov."},{"key":"75386_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1530\/ERC-10-0262","volume":"18","author":"C Thangavel","year":"2011","unstructured":"Thangavel, C. et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr. Relat. Cancer 18, 333\u2013345 (2011).","journal-title":"Endocr. Relat. Cancer"},{"key":"75386_CR9","doi-asserted-by":"crossref","unstructured":"Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: From basic science to cancer therapy. Science 375, eabc1495 (2022).","DOI":"10.1126\/science.abc1495"},{"key":"75386_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison, L., Loibl, S. & Turner, N. C. The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat. Rev. Clin. Oncol. 21, 89\u2013105 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75386_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/ng.3578","volume":"48","author":"CD van Karnebeek","year":"2016","unstructured":"van Karnebeek, C. D. et al. NANS-mediated synthesis of sialic acid is required for brain and skeletal development. Nat. Genet. 48, 777\u2013784 (2016).","journal-title":"Nat. Genet."},{"key":"75386_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf2772","volume":"9","author":"Q Bu","year":"2023","unstructured":"Bu, Q. et al. Neurodevelopmental defects in human cortical organoids with N-acetylneuraminic acid synthase mutation. Sci. Adv. 9, eadf2772 (2023).","journal-title":"Sci. Adv."},{"key":"75386_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108429","volume":"26","author":"Y Quan","year":"2023","unstructured":"Quan, Y., Zhang, H., Wang, M. & Ping, H. Visium spatial transcriptomics reveals intratumor heterogeneity and profiles of Gleason score progression in prostate cancer. iScience 26, 108429 (2023).","journal-title":"iScience"},{"key":"75386_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113736","volume":"430","author":"Q Wu","year":"2023","unstructured":"Wu, Q., Jiang, G., Sun, Y. & Li, B. Reanalysis of single-cell data reveals macrophage subsets associated with the immunotherapy response and prognosis of patients with endometrial cancer. Exp. Cell Res. 430, 113736 (2023).","journal-title":"Exp. Cell Res."},{"key":"75386_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10238-020-00652-1","volume":"20","author":"J Ren","year":"2020","unstructured":"Ren, J. et al. Development and validation of a metabolic gene signature for predicting overall survival in patients with colon cancer. Clin. Exp. Med. 20, 535\u2013544 (2020).","journal-title":"Clin. Exp. Med."},{"key":"75386_CR16","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","volume":"55","author":"X Jin","year":"2023","unstructured":"Jin, X. et al. Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat. Genet. 55, 1696\u20131708 (2023).","journal-title":"Nat. Genet."},{"key":"75386_CR17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","volume":"7","author":"M Fu","year":"2022","unstructured":"Fu, M. et al. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct. Target Ther. 7, 376 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"75386_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246\u2013257 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"75386_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","volume":"19","author":"A Dey","year":"2020","unstructured":"Dey, A., Varelas, X. & Guan, K. L. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat. Rev. Drug Discov. 19, 480\u2013494 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"75386_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","volume":"88","author":"S Ma","year":"2019","unstructured":"Ma, S., Meng, Z., Chen, R. & Guan, K. L. The Hippo Pathway: Biology and Pathophysiology. Annu. Rev. Biochem. 88, 577\u2013604 (2019).","journal-title":"Annu. Rev. Biochem."},{"key":"75386_CR21","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/cdd.2017.99","volume":"24","author":"N Furth","year":"2017","unstructured":"Furth, N. & Aylon, Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ. 24, 1488\u20131501 (2017).","journal-title":"Cell Death Differ."},{"key":"75386_CR22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","volume":"163","author":"FX Yu","year":"2015","unstructured":"Yu, F. X., Zhao, B. & Guan, K. L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811\u2013828 (2015).","journal-title":"Cell"},{"key":"75386_CR23","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","volume":"71","author":"H Murakami","year":"2011","unstructured":"Murakami, H. et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 71, 873\u2013883 (2011).","journal-title":"Cancer Res."},{"key":"75386_CR24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1534\/genetics.113.156372","volume":"195","author":"T Yu","year":"2013","unstructured":"Yu, T., Bachman, J. & Lai, Z. C. Evidence for a tumor suppressor role for the large tumor suppressor genes LATS1 and LATS2 in human cancer. Genetics 195, 1193\u20131196 (2013).","journal-title":"Genetics"},{"key":"75386_CR25","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.cell.2016.11.005","volume":"167","author":"T Moroishi","year":"2016","unstructured":"Moroishi, T. et al. The Hippo Pathway Kinases LATS1\/2 Suppress Cancer Immunity. Cell 167, 1525\u20131539 (2016).","journal-title":"Cell"},{"key":"75386_CR26","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1038\/s41586-020-03131-5","volume":"591","author":"S Ma","year":"2021","unstructured":"Ma, S. et al. Hippo signalling maintains ER expression and ER(+) breast cancer growth. Nature 591, E1\u2013e10 (2021).","journal-title":"Nature"},{"key":"75386_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30831-5","volume":"13","author":"X Li","year":"2022","unstructured":"Li, X. et al. YAP inhibits ER\u03b1 and ER(+) breast cancer growth by disrupting a TEAD-ER\u03b1 signaling axis. Nat. Commun. 13, 3075 (2022).","journal-title":"Nat. Commun."},{"key":"75386_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28691-0","volume":"13","author":"S Ma","year":"2022","unstructured":"Ma, S. et al. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER(+) breast cancer. Nat. Commun. 13, 1061 (2022).","journal-title":"Nat. Commun."},{"key":"75386_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/emboj.2011.357","volume":"31","author":"K Zhang","year":"2012","unstructured":"Zhang, K. et al. Lats2 kinase potentiates Snail1 activity by promoting nuclear retention upon phosphorylation. EMBO J. 31, 29\u201343 (2012).","journal-title":"EMBO J."},{"key":"75386_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/ncb3073","volume":"17","author":"B Ma","year":"2015","unstructured":"Ma, B. et al. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. Nat. Cell Biol. 17, 95\u2013103 (2015).","journal-title":"Nat. Cell Biol."},{"key":"75386_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11123","volume":"7","author":"B Ma","year":"2016","unstructured":"Ma, B. et al. Zyxin-Siah2-Lats2 axis mediates cooperation between Hippo and TGF-\u03b2 signalling pathways. Nat. Commun. 7, 11123 (2016).","journal-title":"Nat. Commun."},{"key":"75386_CR32","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1074\/jbc.RA117.000392","volume":"293","author":"C Zhu","year":"2018","unstructured":"Zhu, C. et al. Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway. J. Biol. Chem. 293, 1178\u20131191 (2018).","journal-title":"J. Biol. Chem."},{"key":"75386_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25145-x","volume":"12","author":"T Yuan","year":"2021","unstructured":"Yuan, T. et al. The Hippo kinase LATS2 impairs pancreatic \u03b2-cell survival in diabetes through the mTORC1-autophagy axis. Nat. Commun. 12, 4928 (2021).","journal-title":"Nat. Commun."},{"key":"75386_CR34","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509\u2013w514 (2020).","journal-title":"Nucleic Acids Res."},{"key":"75386_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s43018-024-00725-0","volume":"5","author":"YZ Jiang","year":"2024","unstructured":"Jiang, Y. Z. et al. Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities. Nat. Cancer 5, 673\u2013690 (2024).","journal-title":"Nat. Cancer"},{"key":"75386_CR36","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.ccell.2023.06.009","volume":"41","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Proteogenomic data and resources for pan-cancer analysis. Cancer Cell 41, 1397\u20131406 (2023).","journal-title":"Cancer Cell"},{"key":"75386_CR37","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen, T. O. et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J. Natl. Cancer Inst. 113, 808\u2013819 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"75386_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr.","year":"2020","unstructured":"Sledge, G. W. Jr. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 6, 116\u2013124 (2020).","journal-title":"JAMA Oncol."},{"key":"75386_CR39","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","volume":"21","author":"JJ Gao","year":"2020","unstructured":"Gao, J. J. et al. CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 21, 250\u2013260 (2020).","journal-title":"Lancet Oncol."},{"key":"75386_CR40","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41571-024-00935-6","volume":"21","author":"MR Lloyd","year":"2024","unstructured":"Lloyd, M. R., Jhaveri, K., Kalinsky, K., Bardia, A. & Wander, S. A. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat. Rev. Clin. Oncol. 21, 743\u2013761 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75386_CR41","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","volume":"19","author":"B Gy\u0151rffy","year":"2021","unstructured":"Gy\u0151rffy, B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct. Biotechnol. J. 19, 4101\u20134109 (2021).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"75386_CR42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bioorg.2005.01.005","volume":"33","author":"ME Tanner","year":"2005","unstructured":"Tanner, M. E. The enzymes of sialic acid biosynthesis. Bioorg. Chem. 33, 216\u2013228 (2005).","journal-title":"Bioorg. Chem."},{"key":"75386_CR43","doi-asserted-by":"publisher","first-page":"17869","DOI":"10.1074\/jbc.M000217200","volume":"275","author":"SM Lawrence","year":"2000","unstructured":"Lawrence, S. M. et al. Cloning and expression of the human N-acetylneuraminic acid phosphate synthase gene with 2-keto-3-deoxy-D-glycero- D-galacto-nononic acid biosynthetic ability. J. Biol. Chem. 275, 17869\u201317877 (2000).","journal-title":"J. Biol. Chem."},{"key":"75386_CR44","doi-asserted-by":"publisher","first-page":"100800","DOI":"10.1016\/j.mcpro.2024.100800","volume":"23","author":"K Fr\u00f6hlich","year":"2024","unstructured":"Fr\u00f6hlich, K. et al. Data-Independent Acquisition: A Milestone and Prospect in Clinical Mass Spectrometry-Based Proteomics. Mol. Cell. Proteom. 23, 100800 (2024).","journal-title":"Mol. Cell. Proteom."},{"key":"75386_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature24451","volume":"550","author":"AP Turnbull","year":"2017","unstructured":"Turnbull, A. P. et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature 550, 481\u2013486 (2017).","journal-title":"Nature"},{"key":"75386_CR46","doi-asserted-by":"publisher","first-page":"32886","DOI":"10.1074\/jbc.M113.496331","volume":"288","author":"KW Lee","year":"2013","unstructured":"Lee, K. W. et al. Herpesvirus-associated ubiquitin-specific protease (HAUSP) modulates peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) stability through its deubiquitinating activity. J. Biol. Chem. 288, 32886\u201332896 (2013).","journal-title":"J. Biol. Chem."},{"key":"75386_CR47","doi-asserted-by":"publisher","first-page":"8355","DOI":"10.1093\/nar\/gkr528","volume":"39","author":"M Felle","year":"2011","unstructured":"Felle, M. et al. The USP7\/Dnmt1 complex stimulates the DNA methylation activity of Dnmt1 and regulates the stability of UHRF1. Nucleic Acids Res. 39, 8355\u20138365 (2011).","journal-title":"Nucleic Acids Res."},{"key":"75386_CR48","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1073\/pnas.1116349109","volume":"109","author":"H Ma","year":"2012","unstructured":"Ma, H. et al. M phase phosphorylation of the epigenetic regulator UHRF1 regulates its physical association with the deubiquitylase USP7 and stability. Proc. Natl. Acad. Sci. USA 109, 4828\u20134833 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75386_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-119","volume":"14","author":"S Lehn","year":"2014","unstructured":"Lehn, S. et al. Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response. BMC Cancer 14, 119 (2014).","journal-title":"BMC Cancer"},{"key":"75386_CR50","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo Phathway. Cancer Cell 34, 893\u2013905 (2018).","journal-title":"Cancer Cell"},{"key":"75386_CR51","doi-asserted-by":"publisher","first-page":"13562","DOI":"10.1073\/pnas.2002630117","volume":"117","author":"G Meinhardt","year":"2020","unstructured":"Meinhardt, G. et al. Pivotal role of the transcriptional co-activator YAP in trophoblast stemness of the developing human placenta. Proc. Natl. Acad. Sci. USA 117, 13562\u201313570 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75386_CR52","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4\/6 inhibitors. Nat. Rev. Clin. Oncol. 13, 417\u2013430 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75386_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/cpcy.64","volume":"91","author":"AJ Schmidt","year":"2019","unstructured":"Schmidt, A. J., Mayer, J. U., Wallace, P. K., Ronchese, F. & Price, K. M. Simultaneous polychromatic immunofluorescent staining of tissue sections and consecutive imaging of up to seven Parameters by standard confocal microscopy. Curr. Protoc. Cytom. 91, e64 (2019).","journal-title":"Curr. Protoc. Cytom."},{"key":"75386_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188903","volume":"1878","author":"G Saha","year":"2023","unstructured":"Saha, G., Roy, S., Basu, M. & Ghosh, M. K. USP7 - a crucial regulator of cancer hallmarks. Biochim. Biophys. Acta Rev. cancer 1878, 188903 (2023).","journal-title":"Biochim. Biophys. Acta Rev. cancer"},{"key":"75386_CR55","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","volume":"22","author":"D Chauhan","year":"2012","unstructured":"Chauhan, D. et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22, 345\u2013358 (2012).","journal-title":"Cancer Cell"},{"key":"75386_CR56","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne, C. K. & Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233\u2013247 (2011).","journal-title":"Annu. Rev. Med."},{"key":"75386_CR57","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2007.15.0946","volume":"26","author":"NU Lin","year":"2008","unstructured":"Lin, N. U. & Winer, E. P. Advances in adjuvant endocrine therapy for postmenopausal women. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 26, 798\u2013805 (2008).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"75386_CR58","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","volume":"22","author":"EL Mayer","year":"2021","unstructured":"Mayer, E. L. et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 22, 212\u2013222 (2021).","journal-title":"Lancet Oncol."},{"key":"75386_CR59","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1056\/NEJMra1307118","volume":"383","author":"HJ Burstein","year":"2020","unstructured":"Burstein, H. J. Systemic therapy forestrogen receptor-positive, HER2-negative Bbreast Cancer. N. Engl. J. Med. 383, 2557\u20132570 (2020).","journal-title":"N. Engl. J. Med."},{"key":"75386_CR60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312929121","volume":"121","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Siglec-15\/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis. Proc. Natl. Acad. Sci. USA 121, e2312929121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75386_CR61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/path.6152","volume":"261","author":"E Scott","year":"2023","unstructured":"Scott, E. et al. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression. J. Pathol. 261, 71\u201384 (2023).","journal-title":"J. Pathol."},{"key":"75386_CR62","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.it.2020.02.001","volume":"41","author":"S van de Wall","year":"2020","unstructured":"van de Wall, S., Santegoets, K. C. M., van Houtum, E. J. H., B\u00fcll, C. & Adema, G. J. Sialoglycans and siglecs can shape the tumor immune microenvironment. Trends Immunol. 41, 274\u2013285 (2020).","journal-title":"Trends Immunol."},{"key":"75386_CR63","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1021\/acschembio.6b00433","volume":"11","author":"RA Kohnz","year":"2016","unstructured":"Kohnz, R. A. et al. Protein Sialylation Regulates a Gene Expression Signature that Promotes Breast Cancer Cell Pathogenicity. ACS Chem. Biol. 11, 2131\u20132139 (2016).","journal-title":"ACS Chem. Biol."},{"key":"75386_CR64","doi-asserted-by":"publisher","first-page":"6827","DOI":"10.2147\/OTT.S177639","volume":"11","author":"EM O\u2019Day","year":"2018","unstructured":"O\u2019Day, E. M., Idos, G. E., Hill, C., Chen, J. W. & Wagner, G. Cytidine monophosphate N-acetylneuraminic acid synthetase enhances invasion of human triple-negative breast cancer cells. OncoTargets Ther. 11, 6827\u20136838 (2018).","journal-title":"OncoTargets Ther."},{"key":"75386_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58569-w","volume":"16","author":"W Ou","year":"2025","unstructured":"Ou, W. et al. Integrated proteogenomic characterization of localized prostate cancer identifies biological insights and subtype-specific therapeutic strategies. Nat. Commun. 16, 3189 (2025).","journal-title":"Nat. Commun."},{"key":"75386_CR66","doi-asserted-by":"publisher","first-page":"8517","DOI":"10.1158\/0008-5472.CAN-10-1242","volume":"70","author":"CA Hall","year":"2010","unstructured":"Hall, C. A. et al. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 70, 8517\u20138525 (2010).","journal-title":"Cancer Res."},{"key":"75386_CR67","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1073\/pnas.0911427107","volume":"107","author":"L Lu","year":"2010","unstructured":"Lu, L. et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. USA 107, 1437\u20131442 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75386_CR68","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s41589-023-01516-x","volume":"20","author":"M Qin","year":"2024","unstructured":"Qin, M. et al. LATS2 condensates organize signalosomes for Hippo pathway signal transduction. Nat. Chem. Biol. 20, 710\u2013720 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"75386_CR69","doi-asserted-by":"crossref","unstructured":"Cheung, P. et al. Regenerative reprogramming of the intestinal stem cell state via Hippo signalings uppresses metastatic colorectal cancer. Cell Stem Cell 27, 590\u2013604 (2020).","DOI":"10.1016\/j.stem.2020.07.003"},{"key":"75386_CR70","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nm.3562","volume":"20","author":"F Cottini","year":"2014","unstructured":"Cottini, F. et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat. Med. 20, 599\u2013606 (2014).","journal-title":"Nat. Med."},{"key":"75386_CR71","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ccell.2021.06.016","volume":"39","author":"JD Pearson","year":"2021","unstructured":"Pearson, J. D. et al. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP\/TEAD activity. Cancer Cell 39, 1115\u20131134 (2021).","journal-title":"Cancer Cell"},{"key":"75386_CR72","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2014.05.001","volume":"26","author":"W Li","year":"2014","unstructured":"Li, W. et al. Merlin\/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell 26, 48\u201360 (2014).","journal-title":"Cancer Cell"},{"key":"75386_CR73","doi-asserted-by":"publisher","first-page":"9423","DOI":"10.1073\/pnas.1821370116","volume":"116","author":"W Kim","year":"2019","unstructured":"Kim, W. et al. Hippo signaling is intrinsically regulated during cell cycle progression by APC\/C(Cdh1). Proc. Natl. Acad. Sci. USA 116, 9423\u20139432 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75386_CR74","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0002-9440(10)65257-1","volume":"154","author":"HX An","year":"1999","unstructured":"An, H. X., Beckmann, M. W., Reifenberger, G., Bender, H. G. & Niederacher, D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am. J. Pathol. 154, 113\u2013118 (1999).","journal-title":"Am. J. Pathol."},{"key":"75386_CR75","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-14-2955","volume":"21","author":"ME Olanich","year":"2015","unstructured":"Olanich, M. E. et al. CDK4 Amplification Reduces Sensitivity to CDK4\/6 Inhibition in Fusion-Positive Rhabdomyosarcoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 21, 4947\u20134959 (2015).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"75386_CR76","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/onc.2016.379","volume":"36","author":"C Yang","year":"2017","unstructured":"Yang, C. et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence. Oncogene 36, 2255\u20132264 (2017).","journal-title":"Oncogene"},{"key":"75386_CR77","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1078-0432.CCR-19-0751","volume":"26","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al.\u00a0Biomarker Analyses of Response to Cyclin-Dependent Kinase 4\/6 Inhibition and Endocrine Therapy in Women with Treatment-Na\u00efve Metastatic Breast Cancer.\u00a0Clin. Cancer Res. Off. 26, 110\u2013121 (2020).","journal-title":"Clin. Cancer Res. Off."},{"key":"75386_CR78","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M \u00c1lvarez-Fern\u00e1ndez","year":"2020","unstructured":"\u00c1lvarez-Fern\u00e1ndez, M. & Malumbres, M. Mechanisms of Sensitivity and Resistance to CDK4\/6 Inhibition. Cancer Cell 37, 514\u2013529 (2020).","journal-title":"Cancer Cell"},{"key":"75386_CR79","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/neuonc\/nos114","volume":"14","author":"L Cen","year":"2012","unstructured":"Cen, L. et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 14, 870\u2013881 (2012).","journal-title":"Neuro Oncol."},{"key":"75386_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1031487","volume":"13","author":"X Sun","year":"2022","unstructured":"Sun, X. et al. HAS2-Ezrin-ER axis plays a role in acquired antiestrogen resistance of ER-positive breast cancer. Front Pharm. 13, 1031487 (2022).","journal-title":"Front Pharm."},{"key":"75386_CR81","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41422-022-00614-0","volume":"32","author":"Y Xiao","year":"2022","unstructured":"Xiao, Y. et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 32, 477\u2013490 (2022).","journal-title":"Cell Res."},{"key":"75386_CR82","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41422-023-00909-w","volume":"34","author":"LP Ge","year":"2024","unstructured":"Ge, L. P. et al. ZNF689 deficiency promotes intratumor heterogeneity and immunotherapy resistance in triple-negative breast cancer. Cell Res. 34, 58\u201375 (2024).","journal-title":"Cell Res."},{"key":"75386_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102659","volume":"7","author":"Y Xu","year":"2026","unstructured":"Xu, Y. et al. Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy. Cell Rep. Med. 7, 102659 (2026).","journal-title":"Cell Rep. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75386-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75386-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75386-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T01:04:26Z","timestamp":1787706266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75386-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75386"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75386-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9029"}}